US gives ProStrakan drug the green light

ProStrakan, the Galashiels-based drugs developer, has secured the rights to sell a fourth drug after the US Food and Drug Administration gave its backing.

Rectiv will become the only FDA-approved prescription product for the treatment of the pain associated with chronic anal fissures.

ProStrakan, which was taken private in March by Japanese peer Kyowa Hakko Kirin in a 300 million deal, said Rectiv sells in Europe as Rectogesic, with sales up 15 per cent in 2010 to 9.3m. Chairman Peter Allen said the US market is significant.